Serum (1-→3) β-D-Glucan as a noninvasive adjunct marker for the diagnosis of pneumocystis pneumonia in patients with AIDS

Clinical Infectious Diseases

Volumn 49, Issue 7, 2009, Pages 1128-1131

  Watanabe, Tamayo ^a,b   Yasuoka, Akira ^c   Tanuma, Junko ^a   Yazaki, Hirohisa ^a,b   Honda, Haruhito ^a   Tsukada, Kunihisa ^a   Honda, Miwako ^a   Gatanaga, Hiroyuki ^a,b   Teruya, Katsuji ^a   Kikuchi, Yoshimi ^a   Oka, Shinichi ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; BETA 1,3 GLUCAN; BETA-1,3-D-GLUCAN; BIOLOGICAL MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; BLOOD; EVALUATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PREDICTION AND FORECASTING;

ADULT; BETA-GLUCANS; BIOLOGICAL MARKERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; PREDICTIVE VALUE OF TESTS;

EID: 70349914153     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605579     Document Type: Article

References (9)

1. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):S5-14. (Pubitemid 30738005)
2. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 2000;356:291-296
3. Cushion MT, Beck JM. Summary of Pneumocystis research presented at the 7th International Workshop on Opportunistic Protists. J Eukaryot Microbiol 2001;48(Suppl):101S-5S.
4. Obayashi T, Yoshida M, Mori T, et al. Plasma (l→3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345:17-20.
5. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1→3) betaD-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996;3:197-199
6. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007;131:1173-1180 (Pubitemid 46608722)
7. Marty FM, Koo S, Bryar J, Baden LR. ( l→3) beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007;147:70-72
8. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-2498
9. Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002;20:982-9. 10. Shimizu A, Oka H, Matsuda T, Ozaki S. (1-3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005;23:678-680 (Pubitemid 35175138)